Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 16Phase 1/2 4Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 3NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 182Docetaxel 166Gemcitabine 165Oxaliplatin 162Carboplatin 160Paclitaxel 152Leucovorin 122Drug Therapy 118Dexamethasone 118Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 56Neoadjuvant Therapy 53Lenalidomide 52Letrozole 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Colony-Stimulating Factors × Clear all
NCT00050531 2016-05-11

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 3 Completed
94 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡